German drugmaker and health care services company Fresenius Kabi has partnered with tech provider Ori Biotech to advance modular, scalable manufacturing of cell and gene therapies.
The collaboration will integrate Ori’s proprietary IRO cell therapy manufacturing platform with Fresenius Kabi’s upstream and downstream processing technologies. The partners have already demonstrated that IRO can be easily and effectively integrated with Fresenius’ Cue and Lovo cell processing systems to deliver an efficient and closed workflow.
“Our collaboration with Ori Biotech allows us to integrate their innovative IRO platform with our systems, supporting our partners’ goal of delivering life-saving cell and gene therapies to patients as quickly and consistently as possible,” said Christian Hauer, president, MedTech, Fresenius Kabi.
Back in October, Fresenius signed a partnership with robotics manufacturing platform developer Cellular Origins to digitally and physically integrate its suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform, Constellation. The aim of the deal is to assist cell therapy developers manufacture their therapies at scale using their preferred processing tools.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!